Mitomycin-C assisted photorefractive keratectomy in the treatment of buttonholed laser in situ keratomileusis flaps associated with epithelial ingrowth.
The prophylactic intraoperative use of mitomycin-C (MMC) to prevent haze and scarring after excimer laser surface ablation (phototherapeutic/photorefractive keratectomy [PTK/PRK]) in an eye with a previous laser in situ keratomileusis (LASIK) flap buttonhole with epithelial ingrowth is described. A well-centered buttonhole measuring 2.0 mm in diameter was cut within a thin LASIK flap in an amblyopic eye. Over the next 8 weeks, corneal haze and progressive epithelial ingrowth formed centrally. An early transepithelial PTK/PRK approach was chosen to manage the buttonhole together with the epithelial ingrowth and to treat ametropia before the onset of scarring. The approach included epithelial removal with PTK, application of MMC 0.02% for 1 minute, irrigation, a short waiting period to allow for diffusion, PRK correction of -4.0 diopters without nomogram adjustment, and bandage contact lens. A regimen of prednisolone acetate 1% and ofloxacin 0.03% 5 times a day for 1 week (steroid tapered) was prescribed. Epithelial ingrowth was removed successfully. Minimal haze formation was visible 2 weeks after the retreatment but did not reduce best spectacle-corrected visual acuity (BSCVA) and resolved within the next few weeks. After 6 weeks, uncorrected visual acuity was equal to BSCVA preoperatively (20/50). There was no evidence of recurrent epithelial ingrowth or central scarring after 24 months. Transepithelial PTK/PRK was effective in managing central epithelial ingrowth in a buttonholed LASIK flap. Prophylactic intraoperative use of MMC may reduce haze formation and corneal scarring in early treatments and may also prevent recurrent epithelial ingrowth. This approach may offer faster visual recovery and no risk for a repeated buttonhole creation compared with the widespread recutting a new flap after a couple of months. The optimal application time and concentration of MMC need to be established.
Taneri
Suphi
S
Zentrum für Refraktive Chirurgie Münster, Münster, Germany. taneri@refractives-zentrum.de
Koch
Jörg M
JM
Melki
Samir A
SA
Azar
Dimitri T
DT
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002921:Cicatrix / Q000517:prevention & control*; D003315:Cornea / Q000473:pathology; D003316:Corneal Diseases / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D048988:Corneal Surgery, Laser; D004359:Drug Therapy, Combination; D019573:Epithelium, Corneal / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D005260:Female; D006801:Humans; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects*; D016685:Mitomycin / Q000627:therapeutic use*; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use*; D015242:Ofloxacin / Q000627:therapeutic use; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D013524:Surgical Flaps / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D019384:Nucleic Acid Synthesis Inhibitors; D016685:Mitomycin; C009935:prednisolone acetate; D011239:Prednisolone; D015242:Ofloxacin